![]() DOR favored the nivolumab arm for patients with lower levels of PD-L1 expression, but the difference did not achieve statistical significance (7.7 vs 6.9 months). In the subgroup of patients with CPS ≥5, nivolumab led to a significantly longer duration of response (DOR 9.7 vs 7.0 months). Similar differences were observed for all levels of PD-L1 expression. Similarly, the overall response rate in all patients was 58% with nivolumab and 46% with chemotherapy alone. The difference represented a 25% reduction in the hazard for disease progression or death (95% CI 0.67-0.84), Shitara reported.Īnalyses by PD-L1 expression showed that the addition of nivolumab improved OS across the range of values from <1 to ≥10 CPS. ![]() PFS2 on first subsequent therapy also favored the nivolumab arm, with median values of 12.2 versus 10.4 months, respectively. The updated analysis showed persistence in the advantages for the nivolumab arm in the form of a 24-month OS rate of 28% versus 19% and a 24-month PFS rate of 16% versus 10%. This may be useful to discuss with the patient regarding the expected benefit." ![]() "PD-L1 may be a negative marker in that most patients with a low level of PD-L1 may respond, but if you use this as a continuous variable, it may be informative about the magnitude of benefit, for instance. "To optimize the treatment we need to address some issues, beginning with how to single out the patients who will or will not respond," said Cascinu. However, the trials left several unanswered questions in their wake. ![]() Together the two trials "cleared the way to immunotherapy in the first-line treatment and will probably change the paradigm of treatment" for advanced gastroesophageal cancer, said invited discussant Stefano Cascinu, MD, of the San Raffaele Research Hospital in Milan. Similarly, the addition of nivolumab had a beneficial effect on OS at all PD-L1 CPS cutoffs but the trial was enriched for higher cutoffs. In the KEYNOTE-590 trial of pembrolizumab, the OS benefits were consistent across all levels of PD-L1 expression but somewhat greater with a combined positive score (CPS) ≥10. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |